H3K27me3 chromatin heterogeneity reveals variable cell responses to estrogen and endocrine treatment
Fleur ChapusiD, Christopher R. DayiD, Laura G. KammeliD, Pelin YaşariD, Brian D. BennettiD, Erica ScappiniiD, Charles J. TuckeriD, Maria I. SifreiD, Celyn Bregio, Joseph RodrigueziD
Abstract
Gene expression heterogeneity generates subpopulations of tumor cells that can evade therapeutic pressure. This heterogeneity has been observed in both primary Estrogen Receptor alpha positive (ER+) breast tumors and cell lines. Therefore, understanding the mechanisms regulating expression heterogeneity is critical towards developing effective therapies. A key contributor to gene expression variability is the stochastic nature of transcription. Transcription occurs in a probabilistic, burst-like manner, in which gene activation occurs intermittently, producing RNA in pulses and interspersed with transcriptional off-periods. The estrogen-responsive gene TFF1 is expressed in the majority of ER breast tumors and exemplifies such heterogeneity, with transcriptional inactivity ranging from minutes to several days. Here, we identify the molecular mechanism underlying the wide range in TFF1 expression by analyzing cells sorted based on their TFF1 activity levels. We observed that TFF1 inactive (TFF1low) cells exhibit a repressive chromatin state marked by H3K27me3 at the TFF1 promoter and enhancer. Despite global similarity in ER binding, occupancy at the TFF1 regulatory elements was selectively reduced in TFF1low cells, resulting in fewer active alleles and diminished transcriptional bursting frequency. Conversely, TFF1high cells exhibited more active TFF1 alleles and hyperbursting. These cells also retained sensitivity to endocrine therapy, while TFF1low cells displayed reduced drug responsiveness. Genome-wide, differentially enriched H3K27me3 regions correlated with variable expression of estrogen-responsive genes, highlighting a broader regulatory mechanism that links chromatin state to expression variability. Together, our findings establish how repressive chromatin dynamics contribute to gene expression heterogeneity and endocrine resistance in ER breast cancer. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=67 SRC="FIGDIR/small/677184v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@1194eedorg.highwire.dtl.DTLVardef@8cb67aorg.highwire.dtl.DTLVardef@202ad9org.highwire.dtl.DTLVardef@1dd222a_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1
S. Gilfillan, S. Wang, … A. Hurtado-Rodriguez·bioRxiv·Sep 22, 2020
- Estrogen receptor regulates hormone-induced growth arrest in a luminal A like breast cancer model
Lacey Haddon, Sunny Hu, … Judith Hugh·bioRxiv·Apr 23, 2018
- Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer
S. Borgoni, E. Sofyali, … S. Wiemann·bioRxiv·Jun 8, 2020
- Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance
- ERα mediated gene state switching regulates the extent of the single-cell estrogen response
C. R. Day, P. Yasar, … J. Rodriguez·bioRxiv·Oct 18, 2023
- Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer
Sarthak Sahoo, Sejal Khanna, … Mohit Kumar Jolly·bioRxiv·May 13, 2026